Boston Scientific
This article was originally published in The Gray Sheet
Executive Summary
Premarket approval application supplement for NIR-On-Ranger coronary stent with Sox securement system is submitted to FDA July 28, the company says. The submission occurs nearly ten months after the firm voluntarily recalled the product on Oct. 5, 1998 due to higher than anticipated balloon failure rates (1"The Gray Sheet" Oct. 12, 1998, p. 28). Recall of the device commenced eight weeks after its launch
You may also be interested in...
Boston Scientific Relying On Primo In Wake Of NIR-On-Ranger With SOX Recall
Boston Scientific expects to generate $150-175 mil. U.S. stent revenue in the fourth quarter despite the firm's Oct. 5 voluntary recall of the NIR-On-Ranger coronary stent system with the SOX securing system.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.